Integrin alpha6beta1 Receptor: A Potential Drug Target and Biomarker

Target Name: Integrin alpha6beta1 Receptor

NCBI ID: P41454

Integrin alpha6beta1 Receptor

Other Name(s): Alpha6beta1 Receptor

Integrin alpha6beta1 Receptor: A Potential Drug Target and Biomarker

The Integrin alpha6beta1 receptor (伪6尾1 integrin) is a cell surface protein that plays a crucial role in many physiological processes in the body. It is a member of the integrin family, which is a large transmembrane protein complex that is involved in cell-cell and cell-matrix interactions. The 伪6尾1 integrin receptor is expressed in many different tissues and cells in the body, including epithelial cells, endothelial cells, and various types of immune cells.

One of the key functions of the 伪6尾1 integrin receptor is its role in cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. The 伪6尾1 integrin receptor helps to regulate cell-cell adhesion by interacting with other proteins on the cell surface, including cadherins and immunoglobulin E (IgE).

Another important function of the 伪6尾1 integrin receptor is its role in cell signaling. The 伪6尾1 integrin receptor can interact with various signaling molecules, including TGF-beta, FGF, and PDGF. These molecules play important roles in regulating cell growth, differentiation, and survival.

The 伪6尾1 integrin receptor is also involved in the regulation of cellular processes such as inflammation and angiogenesis. Integrin 伪6尾1 has been shown to play a role in the regulation of immune cell recruitment and activation, as well as the regulation of angiogenesis, the formation of new blood vessels.

Due to its involvement in these important cellular processes, the 伪6尾1 integrin receptor is a potential drug target. Many researchers are interested in developing drugs that can modulate the activity of the 伪6尾1 integrin receptor in order to treat various diseases.

One approach to targeting the 伪6尾1 integrin receptor is to use small molecules that can modulate its activity. For example, researchers have shown that inhibitors of the 伪6尾1 integrin receptor can be effective in treating various types of cancer, including breast, lung, and colorectal cancer. These inhibitors work by binding to specific residues on the 伪6尾1 integrin receptor and preventing it from interacting with other proteins on the cell surface.

Another approach to targeting the 伪6尾1 integrin receptor is to use antibodies that can specifically recognize and label the receptor. These antibodies can be used to study the structure and function of the 伪6尾1 integrin receptor, as well as to test the effectiveness of potential drugs.

In addition to its potential as a drug target, the 伪6尾1 integrin receptor is also an important biomarker for certain diseases. For example, high levels of 伪6尾1 integrin receptor have been shown to be associated with various types of cancer, as well as with various types of autoimmune diseases. Additionally, the 伪6尾1 integrin receptor is often used as a target for researchers to study the role of cell-cell adhesion in various biological processes.

Overall, the 伪6尾1 integrin receptor is a complex and important protein that plays a crucial role in many cellular processes in the body. Its potential as a drug target and as a biomarker make it an attractive target for researchers to study and develop new treatments for various diseases.

Protein Name: Integrin Alpha6beta1 Receptor

The "Integrin alpha6beta1 Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin alpha6beta1 Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets